Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $3.75 Average PT from Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $3.75.

A number of research analysts have issued reports on HOWL shares. HC Wainwright cut their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Wedbush cut shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price for the company. in a research report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th.

Insiders Place Their Bets

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total transaction of $171,395.36. Following the transaction, the insider owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. This trade represents a 2.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ansbert Gadicke sold 140,488 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total transaction of $171,395.36. Following the transaction, the insider owned 6,007,122 shares of the company’s stock, valued at approximately $7,328,688.84. This represents a 2.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 5,706,681 shares of company stock worth $6,342,622. Insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. MPM Asset Management LLC grew its holdings in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares during the period. MPM Bioimpact LLC lifted its holdings in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Bank of America Corp DE grew its stake in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Vanguard Group Inc. increased its holdings in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics in the second quarter worth about $409,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Stock Up 1.8%

Shares of HOWL opened at $0.64 on Monday. The business’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.27. The firm has a market capitalization of $31.30 million, a price-to-earnings ratio of -0.40 and a beta of 0.77. Werewolf Therapeutics has a 52 week low of $0.56 and a 52 week high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.